Koers Daiichi Sankyo Company, Limited Other OTC
Aandelen
DSNKY
US23381D1028
Farmaceutische producten
Omzet 2024 | 1.602 mld. 10,28 mld. 9,55 mld. | Omzet 2025 * | 1.767 mld. 11,34 mld. 10,53 mld. | Marktkapitalisatie | 10.323 mld. 66,25 mld. 61,52 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 | 201 mld. 1,29 mld. 1,2 mld. | Nettowinst (verlies) 2025 * | 191 mld. 1,22 mld. 1,14 mld. | EV/omzet 2024 | 5,72 x |
Nettoliquiditeiten 2024 * | 556 mld. 3,57 mld. 3,31 mld. | Nettoliquiditeiten 2025 * | 629 mld. 4,04 mld. 3,75 mld. | EV/omzet 2025 * | 5,49 x |
K/w-verhouding 2024 |
45,6
x | K/w-verhouding 2025 * |
52,1
x | Werknemers | - |
Dividendrendement 2024 |
1,05% | Dividendrendement 2025 * |
1,09% | Vrij verhandelbaar | 97,04% |
Recentste transcriptie over Daiichi Sankyo Company, Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01-04-07 |
Hiroyuki Okuzawa
PSD | President | 61 | 01-04-17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 01-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 01-06-19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 01-06-19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01-04-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
+7,68% | 166 mld. |